These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27882588)

  • 1. Clinical and epidemiological analysis in 149 cases of rhododendrol-induced leukoderma.
    Yoshikawa M; Sumikawa Y; Hida T; Kamiya T; Kase K; Ishii-Osai Y; Kato J; Kan Y; Kamiya S; Sato Y; Yamashita T
    J Dermatol; 2017 May; 44(5):582-587. PubMed ID: 27882588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma.
    Fukaya S; Kamata M; Kasanuki T; Yokobori M; Takeoka S; Hayashi K; Tanaka T; Fukuyasu A; Ishikawa T; Ohnishi T; Iimuro S; Tada Y; Watanabe S
    J Dermatol; 2018 Nov; 45(11):1283-1288. PubMed ID: 30156328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Use of Topical Bimatoprost on Rhododendrol-induced Refractory Leukoderma: A Case Report.
    Fukaya S; Kamata M; Kasanuki T; Yokobori M; Takeoka S; Hayashi K; Tanaka T; Fukuyasu A; Ishikawa T; Ohnishi T; Iimuro S; Watanabe S; Tada Y
    Acta Derm Venereol; 2019 Nov; 99(12):1178-1179. PubMed ID: 31449314
    [No Abstract]   [Full Text] [Related]  

  • 4. Glutathione maintenance is crucial for survival of melanocytes after exposure to rhododendrol.
    Kondo M; Kawabata K; Sato K; Yamaguchi S; Hachiya A; Takahashi Y; Inoue S
    Pigment Cell Melanoma Res; 2016 Sep; 29(5):541-9. PubMed ID: 27223685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Leukoderma caused by chemicals: mechanisms underlying 4-alkyl/aryl-substituted phenols- and rhododendrol-induced melanocyte loss].
    Nishimaki-Mogami T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2015; (133):13-20. PubMed ID: 26821466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhododendrol-induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments in comparison with vitiligo.
    Inoue S; Katayama I; Suzuki T; Tanemura A; Ito S; Abe Y; Sumikawa Y; Yoshikawa M; Suzuki K; Yagami A; Masui Y; Ito A; Matsunaga K
    J Dermatol; 2021 Jul; 48(7):969-978. PubMed ID: 33951216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immune pathological and ultrastructural skin analysis for rhododenol-induced leukoderma patients.
    Tanemura A; Yang L; Yang F; Nagata Y; Wataya-Kaneda M; Fukai K; Tsuruta D; Ohe R; Yamakawa M; Suzuki T; Katayama I
    J Dermatol Sci; 2015 Mar; 77(3):185-8. PubMed ID: 25676426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substantial evidence for the rhododendrol-induced generation of hydroxyl radicals that causes melanocyte cytotoxicity and induces chemical leukoderma.
    Gabe Y; Miyaji A; Kohno M; Hachiya A; Moriwaki S; Baba T
    J Dermatol Sci; 2018 Sep; 91(3):311-316. PubMed ID: 30005897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical, cytological, and immunological mechanisms of rhododendrol-induced leukoderma.
    Tokura Y; Fujiyama T; Ikeya S; Tatsuno K; Aoshima M; Kasuya A; Ito T
    J Dermatol Sci; 2015 Mar; 77(3):146-9. PubMed ID: 25726326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depigmentation caused by application of the active brightening material, rhododendrol, is related to tyrosinase activity at a certain threshold.
    Kasamatsu S; Hachiya A; Nakamura S; Yasuda Y; Fujimori T; Takano K; Moriwaki S; Hase T; Suzuki T; Matsunaga K
    J Dermatol Sci; 2014 Oct; 76(1):16-24. PubMed ID: 25082450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhododendrol, a depigmentation-inducing phenolic compound, exerts melanocyte cytotoxicity via a tyrosinase-dependent mechanism.
    Sasaki M; Kondo M; Sato K; Umeda M; Kawabata K; Takahashi Y; Suzuki T; Matsunaga K; Inoue S
    Pigment Cell Melanoma Res; 2014 Sep; 27(5):754-63. PubMed ID: 24890809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukoderma induced by rhododendrol is different from leukoderma of vitiligo in pathogenesis: A novel comparative morphological study.
    Tsutsumi R; Sugita K; Abe Y; Hozumi Y; Suzuki T; Yamada N; Yoshida Y; Yamamoto O
    J Cutan Pathol; 2019 Feb; 46(2):123-129. PubMed ID: 30456919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of discoidin domain receptor 1 and E-cadherin in epidermis affects melanocyte behavior in rhododendrol-induced leukoderma mouse model.
    Abe Y; Hozumi Y; Okamura K; Suzuki T
    J Dermatol; 2020 Nov; 47(11):1330-1334. PubMed ID: 32770866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhododenol-induced leukoderma in a mouse model mimicking Japanese skin.
    Abe Y; Okamura K; Kawaguchi M; Hozumi Y; Aoki H; Kunisada T; Ito S; Wakamatsu K; Matsunaga K; Suzuki T
    J Dermatol Sci; 2016 Jan; 81(1):35-43. PubMed ID: 26547111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zebrafish as a new model for rhododendrol-induced leukoderma.
    Hayazaki M; Hatano O; Shimabayashi S; Akiyama T; Takemori H; Hamamoto A
    Pigment Cell Melanoma Res; 2021 Nov; 34(6):1029-1038. PubMed ID: 34310852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of rhododendrol-induced leukoderma in improved and aggravated cases.
    Yasuda M; Sekiguchi A; Kishi C; Toki S; Arase N; Takahashi A; Yang F; Tanemura A; Hayashi M; Abe Y; Hamada T; Suzuki T; Katayama I; Ishikawa O
    J Dermatol Sci; 2020 Aug; 99(2):140-143. PubMed ID: 32653297
    [No Abstract]   [Full Text] [Related]  

  • 17. Autoantibodies detected in patients with vitiligo vulgaris but not in those with rhododendrol-induced leukoderma.
    Arase N; Tanemura A; Jin H; Nishioka M; Aoyama Y; Oiso N; Matsunaga K; Suzuki T; Nishigori C; Kawamura T; Shimizu T; Ito A; Fukai K; Abe Y; Yang L; Tsuruta D; Takeoka K; Iwatani Y; Hidaka Y; Nishida M; Yamauchi-Takihara K; Arase H; Fujimoto M; Katayama I
    J Dermatol Sci; 2019 Aug; 95(2):80-83. PubMed ID: 31399283
    [No Abstract]   [Full Text] [Related]  

  • 18. The early repigmentation pattern of vitiligo is related to the source of melanocytes and by the choice of therapy: a retrospective cohort study.
    Yang K; Xiong X; Pallavi G; Ling Y; Ding F; Duan W; Sun W; Ding G; Gong Q; Zhu W; Lu Y
    Int J Dermatol; 2018 Mar; 57(3):324-331. PubMed ID: 29318595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oral cholecalciferol on rhododendrol-induced vitiligo: A blinded randomized clinical trial.
    Watabe A; Yamasaki K; Asano M; Kanbayashi Y; Nasu-Tamabuchi M; Terui H; Furudate S; Kakizaki A; Tsuchiyama K; Kimura Y; Ito Y; Kikuchi K; Aiba S
    J Dermatol; 2018 Apr; 45(4):456-462. PubMed ID: 29399865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide association study identifies CDH13 as a susceptibility gene for rhododendrol-induced leukoderma.
    Okamura K; Abe Y; Naka I; Ohashi J; Yagami A; Matsunaga K; Kobayashi Y; Fukai K; Tanemura A; Katayama I; Masui Y; Ito A; Yamashita T; Nagai H; Nishigori C; Oiso N; Aoyama Y; Araki Y; Saito T; Hayashi M; Hozumi Y; Suzuki T
    Pigment Cell Melanoma Res; 2020 Nov; 33(6):826-833. PubMed ID: 32558222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.